Advertisement
|
|
|
|
|
Free Trial
Description: Alfred Mann is MannKind CEO. With a Lead411 subscription, MannKind email addresses ( @mannkindcorp.com ) of the executives are viewable. Other information includes Alfred Mann email, phone, and extension.
We provide information from your LinkedIn network, see company profile, and soon we will be showing twitter profiles as well. Typical management titles include VP, Chief, Vice President, Director, manager, & more. Similar names to Mann can be found at Executive Directory - Mann.
|
Add Alfred Mann Information
Site Reference: http://www.mannkindcorp.com/pressreleasetext.aspx?releaseID=1222249
Alfred Mann Chairman and Chief Executive Officer. "Our pivotal trials are completed and we are well along in preparation of the AFRESA NDA submission to the FDA. We have completed and dedicated our new manufacturing facility and equipped it with the first stage of the modular production systems that will be used to supply commercial product. The emerging data support our belief that AFRESA will be a very important prandial insulin for most people with type 1 and type 2 diabetes. We will soon be ready to reinitiate discussions with potential partners." Conference Call MannKind management will host a conference call to discuss these results today at 9:00 a.m. Eastern Time. To participate in the call please dial (888) 677-5721 or (210) 839-8507. To listen to the call via the Internet please visit http://www.mannkindcorp.com. The web site replay will be available for fourteen days. A telephone replay will be * President and Chief Operating Officer Hakan Edstrom * Corporate Vice President and Chief Financial Officer Matthew Pfeffer * Corporate Vice President and Chief Scientific Officer Peter Richardson About MannKind Corporation MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts
|
|
| Copyright 2010 Lead411 | Santa Barbara, CA |
|
|
|
|
Advertisement
|
